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Abstract. Diethylenetriamine pentaacetic acid penta-ethyl ester, designated as C2E5, was successfully
incorporated into a nonaqueous gel for transdermal delivery. The thermal and rheological properties of a
formulation containing 40% C2E5, 20% ethyl cellulose, and 40% Miglyol 840® prepared using the
solvent evaporation method demonstrated that the gel had acceptable content uniformity and flow
properties. In vitro studies showed that C2E5 was steadily released from the gel at a rate suitable for
transdermal delivery. Topical application of the gel at a 200 mg C2E5/kg dose level in rats achieved
significantly higher plasma exposures of several active metabolites compared with neat C2E5 oil at the
same dose level. The results suggest that transdermal delivery of a chelator prodrug is an effective
radionuclide decorporation strategy by delivering chelators to the circulation with a pharmacokinetic
profile that is more consistent with the biokinetic profile of transuranic elements in contaminated
individuals.
KEYWORDS: nonaqueous gel; pharmacokinetics; radionuclide decorporation; transdermal drug
delivery.
INTRODUCTION
The Fukushima Daiichi nuclear incident in March 2011
attracted world attention to currently available radiological
countermeasures for such disasters. In addition, the threat of
nuclear terrorism resulting from detonation of a radiological
dispersion device (“dirty bomb”) calls for effective medical
countermeasures designed for use in mass casualty scenarios.
In both of these events, significant release of transuranic
radionuclides into the environment could result in human
exposure via inhalation, ingestion, or absorption at a wound
site. The injuries and risks associated with internal deposition
of the transuranic elements americium (Am), curium (Cm),
and plutonium (Pu) can be mitigated by administration of
radionuclide decorporation agents such as the calcium (Ca)
and zinc (Zn) trisodium salts of diethylenetriamine penta-
acetic acid (DTPA), which are the only agents approved by
the US Food and Drug Administration to treat internal
contamination by transuranics. DTPA is a synthetic poly-
amino carboxylic acid with eight coordinate bond forming
sites that can sequester metal ions and form highly stable
DTPA–metal ion complexes. DTPA has wide industrial and
medical applications including control of water hardness,
medical imaging, and decorporation of internally deposited
radionuclides (1). Ca- and Zn-DTPA achieve therapeutic
efficacy by exchanging the Ca and Zn cations with transuranic
radionuclides in vivo to form higher-affinity complexes and
promoting their elimination from contaminated individuals
(2). The high aqueous solubility and low permeability of these
compounds result in poor bioavailability after oral adminis-
tration (3–5). Therefore, these compounds must be adminis-
tered by slow intravenous (i.v.) push, i.v. infusion, or
inhalation using a nebulizer (6). The administration of DTPA
by i.v. or inhalation to those contaminated with transuranic
isotopes requires skilled medical professionals, which imposes
a logistical challenge in a mass casualty setting. As a
consequence, there is an urgent need for new decorporation
treatments that allow patients to self-administer in a timely
manner after a nuclear disaster.
Contamination by radioactive Am, Pu, and Cm can occur
by inhalation, skin adsorption, or by entrance through a
wound. The transfer of these radioactive elements from
experimental deep puncture wounds to the systemic circula-
tion is generally a slow, steady process and transfer rates
ranging from 0.052% to 6.3% of the injected dose per day
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have been observed, depending on the radio-contaminants
and the animal species (7). In contrast, the total body
clearance of 14C-labeled DTPA from rats 24 h after i.v.
administration has been reported to range from 94% to 100%
with the half-life ranging from 18.5 to 31.8 min (8,9).
Comparison of the short half-life and rapid elimination of
DTPA after i.v. injection to the slow introduction of
radioactive actinide species into the bloodstream reveals a
mismatch between the pharmacokinetics of DTPA and the
biokinetic profiles of the actinides, which may limit the
effectiveness of the currently available DTPA treatments.
Transdermal delivery of therapeutic agents provides
many advantages over parenteral and oral routes such as
more uniform plasma drug levels, a longer duration of action
with a reduced dosing frequency, and improved patient
compliance and comfort with ease of self-administration
(10–13). It is highly desirable to deliver decorporation agents
including DTPA to the circulation at a zero-order rate to
better match actinide biokinetic profiles and thus achieve
optimal radionuclide decorporation over an extended dura-
tion. Due to its low partition coefficient (log P0−4.90) and
high melting point (219–220°C), DTPA is not a good
candidate for transdermal delivery (12,14). However, the
penta-ethyl ester of DTPA, designated as C2E5, was designed
and synthesized as a new radionuclide decorporation prodrug
to overcome the limitations of the current DTPA treatments
(15,16). The structures of C2E5 as well as its potential
degradation products and metabolites including DTPA tetra-
ethyl ester (C2E4), DTPA tri-ethyl ester (C2E3), DTPA di-
ethyl ester (C2E2), DTPA mono-ethyl ester (C2E1), and the
fully de-esterified DTPA are shown in Fig. 1. C2E5 possesses
physicochemical properties suitable for transdermal delivery.
It has a log P value of 3.3, a log D value of 2.4 at pH7.0, its
aqueous solubility is 3.0 mg/mL at pH7.0, and it is a
Newtonian liquid with a viscosity of 175 cP at 25°C (16,17).
The aim of these studies was to develop C2E5 transder-
mal formulations and evaluate them for sustained delivery of
DTPA and other active metabolites in vivo. Cream and
ointment formulations were initially screened as potential
C2E5 delivery vehicles, but the results showed that either
C2E5 proved to be unstable in the matrices due to
degradation or the C2E5 formulations underwent phase
separation. C2E5 degradation in buffered aqueous solution
follows pseudo-first order kinetics and C2E5 is most stable at
a pH of approximately 4.2 (17). Due to the high hydrolytic
tendency of the C2E5 ester bonds in aqueous media,
nonaqueous gel formulations were pursued to stabilize the
moisture-labile C2E5 in the delivery vehicles. Many drugs for
topical and transdermal drug delivery are moisture-sensitive
and undergo degradation reactions with water (18). The
major degradation pathway involved with moisture-sensitive
drugs is hydrolysis followed by secondary degradation
reactions such as polymerization and isomerization (19). In
contrast to extensive research on traditional semisolid dosage
forms such as creams, ointments, and hydrogels, there are far
fewer reports on the development of nonaqueous gel matrices
intended for topical and transdermal drug delivery (20–24).
Ethyl cellulose is frequently used as a gelling agent for
nonaqueous gel vehicles. A series of nonaqueous gels with 15
and 20% (% w/w) ethyl cellulose were prepared as topical
formulations of naproxen (20). Lee and colleagues developed
a nonaqueous gel with 3–10% (% w/w) ethyl cellulose
dispersed in an ethanol/tricaprylin (40:60, w/w) mixture (21).
Lizaso and coworkers heated ethyl cellulose and phthalate
ester derivative mixtures to 180°C and formed a nonaqueous
gel during the cooling process (22). The Heng group reported
on nonaqueous gel matrices containing ethyl cellulose and
Miglyol 840®, which is a mixture of propylene glycol
dicaprylate and dicaprate, obtained by directly mixing the
ethyl cellulose and Miglyol 840 at 60°C (23). The rheological,
mechanical, wettability, and spreadability properties of the
ethyl cellulose/Miglyol 840 nonaqueous gels indicate that
these matrices possess favorable attributes for transdermal
and topical delivery (23,25,26). Here, we report on the
preparation and characterization of C2E5 nonaqueous gels
including their physical and rheological properties, determi-
nation of the stability of C2E5 in the gel, in vitro release
properties, and preliminary in vivo pharmacokinetics of the
lead C2E5 nonaqueous gel formulation.
MATERIALS AND METHODS
Materials
Miglyol 840 was purchased from Sasol (Hamburg,
Germany). Ethyl cellulose polymers, including ETHOCEL
Std 7 FP Premium (EC7), ETHOCEL Std 10 FP Premium
(EC10), and ETHOCEL Std 100 FP Premium (EC100) with
an ethoxyl content of 48.0–49.5%, were gifts from Dow
Chemical (Midland, MI, USA). C2E5 was prepared based on
the Fischer esterification method by reacting DTPA with
ethanol under reflux in the presence of a hydrochloric acid
catalyst (17). Acetonitrile, trifluoroacetic acid, anhydrous
ethanol, methanol, isopropyl alcohol, formic acid, iron (III)
Fig. 1. Structures of DTPA, the prodrug C2E5, and its metabolites
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chloride hexahydrate, ammonium formate, tributylamine, and
acetic acid were purchased from VWR International (Rad-
nor, PA, USA) or Fisher Scientific (Fairlawn, NJ, USA).
Double-distilled water was obtained from a Milli-Q system
(Millipore, Billerica, MA, USA).
Preparation of the C2E5 Nonaqueous Gels
The C2E5 nonaqueous gels were prepared using the
solvent evaporation method. The EC10 material was dried at
60°C for ∼24 h before use in gel preparations. Predried EC10
particles were initially dissolved in anhydrous ethanol (10%
w/v of EC10 to ethanol) to form an EC10 stock solution. The
C2E5 nonaqueous gel was prepared by mixing the EC10
stock solution, Miglyol 840 and C2E5 to form a homogenous
solution, followed by removing ethanol under vacuum. When
the gel was <102% of the theoretical weight, the C2E5
nonaqueous gels were transferred to a storage container
under nitrogen and sealed with an airtight cap, covered with
aluminum foil to protect from light, and stored at 4°C for
later use.
The C2E5 concentration in these gel formulations was
determined using a Shimadzu Prominence high pressure
liquid chromatography (HPLC) system equipped with an
Alltech 3300 evaporative light scattering detector (ELSD). A
reverse-phase gradient separation was performed using an
Alltima C18 column (250×2.1 mm I.D., 5 μm) at 40°C and a
flow rate of 0.25 mL/min. The solvents that comprised the
mobile phase were water with 0.1% trifluoroacetic acid (A),
acetonitrile (B), and isopropyl alcohol (C). The linear
gradient for the mobile phase mixture (A/B/C) was from
94:4:2 to 25:50:25 over 35 min, followed by a change to 0:0:100
in 0.5 min and an equilibration phase of 0:0:100 for 9.5 min,
and ending with a reversal to 94:4:2 in 0.5 min and an
equilibration phase of 94:4:2 for 9.5 min. The ELSD was
operated at 40°C with 1.9 L/min nitrogen gas flow. Triplicate
injections for each sample of C2E5 nonaqueous gel dissolved
in anhydrous ethanol were performed with a volume of 10 μL
per injection, and the retention time of C2E5 was 26 min.
Samples were held at ambient temperature during analysis
and analyzed using a standard curve over a concentration
range of 0.02–2.00 mg/mL, which had a power regression fit
of R200.999. C2E5 nonaqueous gel samples stored at 4°C for
6 months were monitored for C2E5 degradation using this
HPLC method.
Physical characterization, in vitro release testing and
pharmacokinetic studies were performed with a formulation
comprised of 20% EC10, 40% C2E5, and 40% Miglyol 840
prepared using the solvent evaporation method.
Differential Scanning Calorimetry
The EC10 polymer particles and the C2E5 nonaqueous
gel samples were analyzed using a TA Instruments differen-
tial scanning calorimetry (DSC) Model Q200 under a
nitrogen flow of 50 mL/min. Approximately 5–10 mg samples
were heated in a sealed aluminum pan at a ramp rate of 10°C/
min, cooled at a rate of 5°C/min, and subsequently heated at
10°C/min in heat/cool/heat mode from −10 to 160°C. The
glass transition (Tg) and melting (Tm) temperatures in the
third heating cycle were determined using TA Universal
Software.
Rheological Measurements
A stress-controlled cone-and-plate rheometer (TA
Instruments, Model AR-G2) with a cone of 40 mm in
diameter and 1° cone angle at controlled temperatures of 25
±0.5°C and 32±0.5°C was utilized to measure continuous
shear rheometry of the nonaqueous gels with a formulation
comprised of 20% EC10, 40% C2E5, and 40% Miglyol 840
prepared using the solvent evaporation method. The gel
samples were carefully loaded to the lower plate to reduce
shearing effects and equilibrated for 5 min at the designated
temperatures prior to measurement. Fresh samples were used
for each individual measurement, and triplicate measure-
ments were performed for the formulation. Data are reported
as mean±SD.
Continuous shear rheometry was obtained by changing
the shear rate from 0.1 to 40 s−1 over a period of 300 s. The
power law equation for simple steady shear (Eq. 1) was used
to fit the data obtained from the upward flow curves (27):
t ¼ m gn

ð1Þ
where τ0shear stress, g
 ¼ shear rate , m0consistency index,
and n0flow behavior index.
The estimated yield stress was derived by fitting the data
using the Casson model described in Eq. 2 (27):
t1=2 ¼ t1=2y þ η g
 1=2
for t  ty ð2Þ
where τy0yield stress and η0creep viscosity. The square root
of yield stress τy was obtained from the plot as the y-axis
intercept when g
 ¼ 0 .
In Vitro Release of C2E5 Nonaqueous Gel
An in vitro release study was carried out using a vertical
diffusion cell system equipped with an autosampler (Hanson
Microette Autosampling System, Hanson Research Co.,
USA) to evaluate the nonaqueous gel formulations com-
prised of 20% EC10, 40% C2E5, and 40% Miglyol 840
prepared using the solvent evaporation method. The area for
permeation was 1.767 cm2, and the receiver compartment
volume was 7 mL. The receiver medium was 0.1 M phosphate
buffer (pH7.4) maintained at 32°C and continuously stirred at
400 rpm. A cellulose acetate membrane (25 mm in diameter,
with a 0.45 μm pore diameter, Whatman®) was first treated
by soaking in the receiving medium and then mounted and
clamped between the receiver and donor compartments of
the diffusion cells. Approximately 300 mg of C2E5
nonaqueous gel was loaded evenly on the surface of the
cellulose acetate membrane (n05) and covered with a glass
disk to exclude air. One-milliliter samples were removed from
the receiver compartment at 0.5, 1, 2, 4, and 6 h, which were
replaced with an equal volume of fresh media.
The C2E5 content in the collected samples was deter-
mined by the HPLC method described above. The cumula-
tive amount of C2E5 released per unit membrane area from
the tested nonaqueous gel was plotted as a function of the
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square root of time and as a function of time. The Higuchi
equation (Eq. 3) dictates the drug release from semisolid
dosage forms including creams, gels, and ointments, and holds








where Q0amount of drug released per unit area (mg/cm2),
Cveh0 initial drug concentration (mg/cm
3) in the vehicle, D0
apparent diffusion coefficient (cm2/h), t0time (h), and π0
constant. The release rate constant k of C2E5 from the
nonaqueous gel formulation was determined using a
simplified form of the Higuchi equation (Eq. 4):
Q ¼ k ffiffitp ð4Þ
where k is the release rate constant, which is determined from
the slope of the cumulative amount of C2E5 released per unit
membrane area from the nonaqueous gel versus the square
root of time.
Fick’s law (Eq. 5) has been used as a simple model to





where Jss0steady-state flux (mg/h), D0drug diffusivity (cm
2/
h), h0membrane thickness (cm), Kp0drug’s membrane-
vehicle partition coefficient, Cveh0 initial drug concentration
(mg/cm3) in the vehicle, and A0surface area (cm2). Jss can be
determined from the slope of the linear plot in the steady-
state region of the cumulative amount of C2E5 permeated
(mg) per unit diffusion surface (cm2) versus a function of
time.
Throughout the experiment the C2E5 concentration in
the receptor compartment was kept below 30% of the
solubility of C2E5 at pH7.4, which is about 2.2 mg/mL at
room temperature (17). Therefore, steady-state flux condition
and sink condition were maintained for the duration of the
experiment.
Absorption of C2E5 Administered as a Neat Oil
or as a Nonaqueous Gel
All animal studies were conducted according to a
protocol approved by the University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee.
Ten-week-old adult female Sprague–Dawley (SD) rats weigh-
ing 200–300 g were used in these studies (Charles River Labs,
Raleigh, NC, USA). Food and water were provided ad
libitum. The animal room was kept at a controlled tempera-
ture on a 12 h/12 h light/dark cycle (light exposure from 7AM
to 7PM). For the duration of the study, the rats were
individually housed in metabolic cages until euthanasia at
24 h after neat C2E5 oil or C2E5 gel application.
In all animals, the dorsal skin between the cervical
vertebrae and anterior thoracic vertebrae of SD rats was
carefully clipped prior to drug application to remove hair.
C2E5 nonaqueous gel was applied at a C2E5 dose of 200 mg/
kg to a 2×3 cm region using a cotton swab. For comparison,
neat C2E5 oil (200 mg/kg) was applied using a 1-mL syringe
to the same size area on a control group of rats. For each rat,
the mass of the drug and applicator was recorded before and
after application with the difference being the delivered dose.
Finally, a jacket with a dermal insert (VWR International,
Radnor, PA, USA) was placed on the rats to protect the
applied treatments. Blood samples (0.4 mL) were collected
from the tail vein using SurFlash® polyurethane i.v. catheters
(Terumo, Somerset, NJ, USA) at either before or 0.5 h after
treatment and then at 1, 2, 4, 8, 12, and 24 h after treatment.
The collected samples were immediately transferred from the
syringes into prechilled sampling tubes containing 5 mg
sodium fluoride and 4 mg potassium oxalate (BD Vacutainer
product number 367921). The tubes were inverted eight times
per manufacturer’s recommendation and centrifuged
(1,300×g for 10 min at 4°C). Plasma samples were then
portioned into two 1.7-mL Eppendorf tubes, which contained
an equal amount of a 20% formic acid aqueous solution.
These tubes were immediately vortexed and placed on dry ice
until transfer to storage at −80°C until analysis. The animals
were transferred to individual housing in metabolic cages
after C2E5 treatment. Animals were euthanized 24 h after
C2E5 gel or neat C2E5 oil application. The animals were
observed during the study period, and the body weight of
each animal was recorded at predose and prior to necropsy.
A liquid chromatography–tandem mass spectrometry
(LC/MS/MS) method was developed for the analysis of
C2E5 and metabolites except for the fully de-esterified
metabolite, DTPA, in these samples. Acidified plasma
samples (100 μL) were first treated with 25 μL of 13C-C2E5
stable-label internal standard (1,000 ng/mL), followed by
precipitation with acetonitrile (400 μL). The supernatant
(400 μL) was removed and evaporated to dryness, and the
residue was reconstituted with 500 μL of 85/15/0.1% water/
acetonitrile/formic acid. A 10-μL injection was used for LC/
MS/MS analysis. Reverse-phase chromatography was
performed at 0.3 mL/min on a YMC® ODS-AM C18 (100×
2 mm, 3 μm) column with mobile phases A (0.1% formic acid
in water) and B (0.1% formic acid in acetonitrile) using a 10-
min gradient (isocratic at 13% mobile phase B for 1 min,
linear gradient to 50% mobile phase B at 6 min, linear
gradient to 60% mobile phase A at 6.5 min, linear gradient to
90% mobile phase B at 8 min, return to initial 13% mobile
phase B at 8.1 min, and equilibrate at 13% mobile phase B
until 10 min). After separation by liquid chromatography, the
analytes and internal standard were detected on a triple
quadrupole mass spectrometer using heated electrospray
ionization (HESI-II) (Thermo Scientific) in the positive-ion
mode. Suitable reference standard material was available to
provide reliable results for C2E5, C2E4, and C2E2. Although
reference standard material was not available for C2E3 and
C2E1, these analytes were present as trace impurities in the
reference standards for C2E5, C2E4, and C2E2. The
assumption of response factors for C2E3 and C2E1 equal to
those of the reference standards afforded an estimate of the
concentrations of C2E3 and C2E1 in calibration standards;
this allowed the generation of calibration curves for C2E3
and C2E1 that were used to estimate the levels of these
analytes in samples. Due to lack of pure internal standards for
C2E3 and C2E1, the plasma concentrations of C2E3 and
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C2E1 in the samples were considered as estimates. The lower
limit of quantification (LLQ) for C2E5, C2E4, C2E3, C2E2,
and C2E1 were determined to be 5.0, 10.0, 1.0, 10.0, and
5.0 ng/mL, respectively.
For detection of DTPA, acidified plasma samples
(100 μL) were first treated with 50 μL of 2 mM iron(III)
chloride hexahydrate, followed by addition of 400 μL of 13C-
DTPA stable-label internal standard (100 ng/mL in 0.1%
acetic acid in acetonitrile). This solution was vortexed for
5 min and then centrifuged at 3,000 rpm for 10 min. The
supernatant (350 μL) was removed, evaporated to dryness,
and reconstituted with 100 μL of 0.1% aqueous acetic acid. A
10-μL aliquot of the reconstituted sample was used for LC/
MS/MS analysis. The highly polar nature of DTPA required
the incorporation of ion-pairing chromatography to produce
acceptable LC peak shape and retention. Mobile phase Awas
90:10 water/methanol with 1 mM ammonium formate and
1 mM tributylamine, and mobile phase B was 50:50
acetonitrile/(5:95 water/methanol) with 1 mM acetic acid
and 1 mM tributylamine. A 10 min gradient was used to
afford separation (isocratic at 5% mobile phase B for 1 min,
linear gradient to 80% mobile phase B at 7 min, linear
gradient to 90% mobile phase B at 7.1 min, maintaining at
90% mobile phase B through 8 min, return to initial 5%
mobile phase B at 8.1 min, and equilibrate at 5% mobile
phase B until 10 min). Reverse-phase chromatography was
performed at 0.3 mL/min on an Advanced Materials
Technology HALO® Phenyl-Hexyl column (50×2.1 mm,
2.7 μm). The analyte and internal standard were detected
on a triple quadrupole mass spectrometer using HESI-II in
the negative-ion mode. The LLQ for DTPA was determined
to be 10.0 ng/mL.
For C2E5 and its metabolites in the pharmacokinetic
samples, plasma concentrations below the limit of quantifica-
tion were labeled as not detected (ND) and assigned a value
of zero for the area under the curve (AUC) analysis. The
AUCs were calculated using the trapezoidal method.
Statistical Analyses
The concentrations of C2E2 and C2E3 in plasma samples
collected at different times from the two C2E5 dosage forms
(neat oil and nonaqueous gel) were compared by unbalanced
two-way analysis of variance (ANOVA). Analysis of the
calculated exposure to C2E3 and C2E2 was by two-tailed t
test. All measurements are expressed as mean±standard
deviation (SD). The level of significance was set at p<0.05.
RESULTS
Preparation of C2E5 Nonaqueous Gels
The solvent evaporation method was used to prepare the
C2E5 nonaqueous gel formulations. To maximize C2E5
loading in the gel and achieve desirable rheological and
mechanical properties, a formulation that contained 40%
C2E5, 20% EC10, and 40% Miglyol 840 was prepared and
yielded a slightly yellow translucent gel, which was deter-
mined to have a density of 1.02 g/cm3. Based on the HPLC
analysis, the C2E5 content in nonaqueous gel samples stored
at 4°C for 6 months contained 98.2% of the C2E5 content in a
freshly prepared C2E5 nonaqueous gel, with C2E4 being as
the main degradant.
Thermal Analysis by DSC
The DSC thermogram of predried EC10 showed one
minor endothermic peak appearing at 63°C and one major
endothermic peak at 120°C. The endothermic peak at 120°C
is the EC10 glass transition temperature (30). The endother-
mic peak at 63°C may be the result of the presence of glyoxal,
an impurity in ethyl cellulose (19), or glyoxal reaction
products. However, further investigation is necessary for
confirmation of this peak. The DSC thermogram of the
C2E5 nonaqueous gel containing 20% EC10, 40% C2E5, and
40% Miglyol 840 prepared using the solvent evaporation
method showed no prominent endothermic peaks in the
range from −10 to 160°C. Complete dissolution of the EC10
in ethanol prior to gel formation eliminated the EC10 glass
transition endothermic peak at 120°C. The impurity in EC10,
which showed the endothermic peak at 63°C on the DSC
thermogram of predried EC10, could possibly have been
dissolved in ethanol and later removed during the solvent
evaporation process, either through direct evaporation (the
boiling point of glyoxal is 51°C) or by formation of an
azeotrope with ethanol. The residual water content in the gel
components could also have been effectively removed during
the solvent evaporation process by formation of an azeotrope
with ethanol.
Rheological Measurement Results
Rheograms derived from continuous shear rheometry
(Fig. 2) demonstrated that the C2E5 nonaqueous gel is a
typical shear-thinning system at both 25 and 32°C. The shear
stress versus shear rate rheogram exhibits a convex shape and
a hysteresis loop. The rheological properties of the 40%
C2E5 nonaqueous gel at different temperatures are
Fig. 2. Continuous shear rheogram showing shear rate versus shear
stress at 25°C and 32°C of C2E5 nonaqueous gel comprised of 20%
EC10, 40% C2E5, and 40% Miglyol 840 prepared using the solvent
evaporation method
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summarized in Table I. The flow behavior index values (n)
were below 1 for both the 25 and 32°C measurements,
indicating a shear-thinning gel structure under each of these
temperature conditions (31). Yield stress and hysteresis area
are parameters representing the rigidity and cohesion be-
tween the molecules forming a three-dimensional gel struc-
ture and the extensiveness of this three-dimensional gel
structure (32,33).
In Vitro Release of C2E5 Nonaqueous Gel
A plot of the cumulative amount of C2E5 released per
unit membrane area versus the square root of time, for the
lead nonaqueous gel (20% EC10, 40% C2E5, and 40%
Miglyol 840), is presented in Fig. 3. The cumulative amount of
C2E5 released per unit membrane area from the lead
nonaqueous gel versus the square root of time yielded a
linear plot with y01.57x–0.78 and R200.996. The amounts of
C2E5 released after 6 h from the five individual in vitro
release runs ranged from 2.89 to 3.33 mg/cm2, with an average
value of 3.11±0.17 mg/cm2 (coefficient of variance05.5%).
The average release rate constant k and average steady-state
flux Jss per unit area of the 40% C2E5 nonaqueous gel were
determined to be 1.57±0.09 mgcm−2h−0.5 and 0.556±
0.031 mgcm−2 h−1, respectively, with both having a
coefficient of variance of 5.6%. For each individual run, an
acceptable linear regression fit was achieved for the release
rate constant k per unit area (R2≥0.994) and the steady-state
flux Jss per unit area (R
2≥0.969).
Absorption of C2E5 Administered as a Neat Oil
or as a Nonaqueous Gel
Following topical application of either the neat C2E5 oil
or the 40% C2E5 nonaqueous gel, the principal circulating
metabolites detected in plasma were C2E3 and C2E2. The
concentrations of C2E3 and C2E2 detected in the rat plasma
samples plotted versus time for the neat C2E5 oil and the
40% C2E5 nonaqueous gel groups are presented in Figs. 4
and 5, respectively. Two-way ANOVA showed that the C2E5
dosage form had a significant effect on the plasma concen-
tration of both C2E2 [FFormulation(1,36)013.3, p<0.001] and
C2E3 [FFormulation(1,36)06.91, p<0.05]. The time the plasma
was sampled was not a significant factor for either metabolite
[C2E2, FTime(7,36)01.06, p00.41 and C2E3, FTime(7,36)00.84,
p00.56], and no interaction between dosage form and time
was observed [C2E2, FInteraction(7,36)00.84, p00.56 and C2E3,
FInteraction(7,36)01.04, p00.42]. The pharmacokinetic parame-
ters of C2E3 and C2E2 after application of neat C2E5 oil or
40% C2E5 nonaqueous gel at 200 mg/kg dose (n04) are
shown in Table II. We observed a trend for increased
exposure to the metabolites C2E3 and C2E2 following
C2E5 application as a nonaqueous gel compared with
application as the neat oil; however, this trend did not reach
statistical significance for either metabolite alone (AUCC2E2,
p00.073 and AUCC2E3, p00.087; both two-tailed t test).
Enhancement ratios based on the AUCs for C2E3 and
C2E2 were determined to compare the AUC obtained from
the 40% C2E5 nonaqueous gel group to the neat C2E5 oil
group.
There was only two plasma samples in which C2E5 was
detected with a concentration above the LLQ among the 56
samples, one from the neat C2E5 oil group (28.4 ng/mL at
2 h) and one from the C2E5 nonaqueous gel group (7.2 ng/
mL at 24 h). There were five plasma samples in which C2E4
was detected with a concentration above the LLQ among 56
samples, three from the neat C2E5 oil group (13.5 ng/mL at
0.5 h, 52.7 ng/mL at 2 h and 45.1 ng/mL at 24 h), and two
from the C2E5 nonaqueous gel group (59.9 ng/mL at 1 h and
83.8 ng/mL at 2 h).
C2E3 and C2E2 species were consistently detected in the
plasma samples from both groups throughout the experimen-
tal period with the Cmax values ranging from 85.3 to 485 ng/
mL for C2E3 and from 17.4 to 413 ng/mL for C2E2,
indicating that C2E3 and C2E2 are stable C2E5 metabolites
in vivo. The concentrations of C2E3 and C2E2 reported in
















25 0.407±0.013 691±17 177±1 663±18 16.7±0.7
32 0.462±0.005 446±13 129±3 381±14 7.71±0.28
aApparent viscosity at a shear rate of 10 s−1
Fig. 3. Relationship between square root of time and cumulative
amount of C2E5 released through a cellulose membrane into 0.1 M
phosphate buffer after application of C2E5 nonaqueous gel (n05).
The C2E5 nonaqueous gel consisted of 20% EC10, 40% C2E5, and
40% Miglyol 840. The release rate constant k is determined from the
slope of the cumulative amount of C2E5 released per unit membrane
area from the tested nonaqueous gel versus square root of time
defined in Eq. 4
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the rat plasma samples versus time figures showed a sustained
release profile from transdermal neat C2E5 oil and C2E5
nonaqueous gel formulations. Average steady-state concen-
trations (Css) for both C2E3 and C2E2 were between 100 and
200 ng/mL for the C2E5 nonaqueous gel group and between
20 and 80 ng/mL for the neat C2E5 oil group. Overall
systemic exposures to C2E3 and C2E2 were approximately
2.9- and 4.2-fold (based on AUC0−24 h) higher for the C2E5
nonaqueous gel group compared to the neat C2E5 oil group.
There was no C2E1 detected above the quantification
limit in any rat plasma samples for either the neat C2E5 oil
group or the C2E5 nonaqueous gel group during the
experimental period. DTPA was frequently detected in the
plasma samples at time points after 4 h postdosing for both
the neat C2E5 oil group and the C2E5 nonaqueous gel group.
Most of the detected DTPA plasma concentrations were in
the range of 10 ng/mL to 30 ng/mL, which is just above the
LLQ of DTPA (10 ng/mL). The maximum DTPA concentra-
tion detected in plasma in the neat C2E5 oil group was
61.4 ng/mL, compared with 693 ng/mL in the C2E5 nonaque-
ous gel group.
DISCUSSION
Nonaqueous gel formulations have been a useful vehicle
for moisture-sensitive drugs for topical and transdermal
application (20–24). Critical components for the successful
development of a semisolid product for topical and transder-
mal applications include the stability of the active pharma-
ceutical ingredient (API) in the delivery matrix, product
uniformity, and the release profile of API from the delivery
matrix. In this study, we report on the development and
characterization of a nonaqueous gel formulation that stabil-
izes the hydrolysis-prone API, enhances its percutaneous
permeation flux, and improves its pharmacokinetic profile
following topical application to rats.
Candidate nonaqueous gel formulations showed im-
proved stability of C2E5 under various storage conditions
when compared with the neat API and other tested delivery
vehicles, such as creams and ointments (34,35), suggesting a
clear benefit of the ethyl cellulose based nonaqueous gel for
this moisture-sensitive compound. The enhanced stability
profile of C2E5 in the nonaqueous gel matrix is probably
due to decreased interactions with the hydroxyl groups on the
ethyl cellulose polymer chains. These hydroxyl groups are not
readily available to interact with other molecules compared to
the hydroxyl groups in small molecule due to steric and
rotational hindrance. The use of Miglyol 840 neutral oil as a
dispersion medium also contributes to the enhanced stability
of C2E5 in the gel matrix because Miglyol 840 is nonhygro-
scopic, possesses high stability against oxidation, and contains
no free hydroxyl groups (23).
Modification of the published direct mixing method for
gel preparation (23), using anhydrous ethanol to dissolve the
ethyl cellulose before forming the gel and then evaporating
the ethanol from the gel mixture, resulted in a significant
improvement in gel uniformity. Although the solvent evapo-
ration method is a commonly used technique for making
films, microspheres, and solid dispersions (36–38), to our
knowledge, this method has not been reported previously for
preparation of ethyl cellulose based nonaqueous gels. To
minimize the amount of solvent used in the gel preparation,
EC7 and EC10 were selected because much more ethanol is
needed to dissolve EC100 than for equal amounts of EC7 or
EC10. Our method of gel preparation requires simple
evaporation of the solvent and is suitable for scale-up, with
ethanol content in the gels readily reduced to below 2% of gel
weight. The solvent evaporation method was successfully
scaled up to prepare 400 g of C2E5 nonaqueous gels in one
batch. Any residual ethanol present in the gel system would
not interact with the C2E5 molecules and might possibly
retard its hydrolysis. Ethanol is approved for human use in
commercial topical and transdermal products at relatively
high concentrations as a basic component and can act as a
permeation enhancer by changing the characteristics of the
skin (23,39). A C2E5 formulation screening study was carried
out and phase separation was observed in gels with low EC
content (<10%) and particularly in gels with lower molecular
weight EC chains. This phase separation may be due to a
decrease in the interactions between the gel matrix and the
C2E5 dissolved in it (data not shown). A C2E5 nonaqueous
gel formulation comprised of 20% EC10, 40% C2E5, and
40% Miglyol 840 was chosen as a candidate formulation for
further physical characterization and in vivo pharmacokinetic
evaluation.
The stability study with the 40% C2E5 nonaqueous gel
showed that <2% of C2E5 had degraded after being stored at
4°C for 6 months, suggesting an acceptable stability profile of
Fig. 4. Concentration of C2E3 detected in rat plasma versus time
after topical administration of the neat C2E5 oil and the 40% C2E5
nonaqueous gel (mean±SD) (n04)
Fig. 5. Concentration of C2E2 detected in rat plasma versus time
after topical administration of the neat C2E5 oil and the 40% C2E5
nonaqueous gel (mean±SD) (n04)
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this formulation.As demonstrated by theDSC thermograms, the
slightly yellow translucent C2E5 nonaqueous gel possessed
acceptable uniformity. This was a result of EC10 being com-
pletely solubilized in ethanol before incorporation into the gel
matrix and thus eliminating the problems related to residual EC
particulates encountered when using the direct mixing method.
The rheological and mechanical properties of the
nonaqueous gel matrices containing ethyl cellulose and
Miglyol 840 were investigated in detail by the Heng group
(23). The rheological properties of the C2E5 nonaqueous gel
comprised of 20% EC10, 40% C2E5, and 40% Miglyol 840
(Table I) exhibited characteristics and flow patterns similar to
nonaqueous gels comprised of ethyl cellulose and Miglyol
840, suggesting that an adequate adhesion force to the skin
surface for prolonged periods could be maintained, a critical
property for the sustained delivery of drug substance from
the gel (40). Other characteristics, such as a 36.6% decrease
in viscosity from 177 (Pas) to 129 (Pas) and a 117% decrease
in hysteresis area with a temperature increase from 25 to 32°
C, are good indicators that the gel is suitable for application
on human skin with a surface temperature of 32–34°C.
The in vivo pharmacokinetic studies using this gel
formulation confirmed the predictions based on these
physical measurements; the gel spread easily during
application and remained at the application site for the
entire study. In contrast, neat C2E5 oil presented a
challenge for application to the skin and retention at the
application site due to its lower viscosity.
In vitro release testing is widely used to assess content
uniformity and drug release from semisolid products and can
also be used to compare performance across different batches
and after storage or changes in the manufacturing process
(41,42). Although transdermal delivery of C2E5 to the
systemic circulation is a multistep process, in vitro release
results suggest that C2E5 is readily released from the
nonaqueous gel matrix and the steady state flux (0.556±
0.031 mgcm−2h−1) associated with this release is expected
provide the required sustained concentration of drug in
plasma. The narrow distribution of the release rate constant
(1.57±0.09, coefficient of variance05.6%) confirmed the
optimal content uniformity of the 40% C2E5 nonaqueous
gel prepared by solvent evaporation method.
Pharmacokinetic data obtained from in vivo studies
confirmed our observations from the in vitro release testing,
with metabolites of C2E5 detected in plasma throughout the
collection period. Additionally, an improved plasma pharma-
cokinetic profile for drug released from the C2E5 nonaque-
ous gel compared with the neat C2E5 oil suggests that
Miglyol 840, a major component of the gel, perhaps along
with residual ethanol in the gel, are working as permeation
enhancers (23,39,43). The enhanced ratios of systemic
exposure to major C2E5 metabolites (C2E3 and C2E2) with
C2E5 nonaqueous gel were greater than those observed with
neat C2E5 oil. The pharmacokinetic data also support our
hypothesis that the mismatch between the biokinetics of
transuranic contaminants and the pharmacokinetics of DTPA
used to treat contamination could be overcome using a
transdermal prodrug strategy.
C2E5 and C2E4 were only detected in concentrations
above their respective LLQs in <10% of all samples;
detection of C2E4 suggests that it is a direct metabolite of
C2E5 in vivo, generated by a stepwise de-esterification
process involving esterases in the rat skin and plasma
(44,45). C2E2 and C2E3 were observed as the principal
metabolites detected in circulation throughout the 24 h study
period, matching the findings of the C2E5 in vitro metabolism
study (44,45). C2E1 was not detected above the LLQ in
any plasma samples throughout the study, but is likely
present transiently resulting from the stepwise de-esterifi-
cation of C2E5 to DTPA. Detection of DTPA at low
concentrations, close to the 10 ng/mL LLQ, was not
unexpected as DTPA has a short half-life ranging from 18.5 to
31.8 min (8,9).
In addition to DTPA, other metabolites, such as C2E3,
C2E2, and C2E1, may effectively sequester transuranic
radionuclides and form stable complexes. For example,
241Am, an abundant transuranic radionuclide, forms
complexes with various chelators, including DTPA and
other molecules structurally similar to C2E3, C2E2, and
C2E1, with stability constants ranging from 10.7 to 24.0 M−1
(46). Although stability constants for americium binding to
C2E5 metabolites are not known, the binding of Gd3+ with
DTPA mono-propyl ester and DTPA di-propyl ester
(compounds analogous to C2E1 and C2E2) are reported to
be 18.91 and 16.30 M−1 (47). Because gadolinium is viewed as
a biochemical analogue of americium and Gd3+ ion is
structurally very similar to 241Am3+ (48,49), comparable
binding constants and thermodynamic stability can be
Table II. Pharmacokinetic Parameters of C2E3 and C2E2 After Application of Neat C2E5 Oil or 40% C2E5 Nonaqueous gel at a C2E5 Dose
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0.281±0.159 4.5±4.0 3.52±2.26 0.203±0.161 4.5±2.5 2.75±1.89
Cmax maximum plasma concentration during 0–24 h period, Tmax time of maximum plasma concentration during 0–24 h period, AUC0–24 h area
under the curve during 0–24 h period
530 Zhang et al.
expected for the binding of 241Am3+ with C2E1 and C2E2 in
vivo. Furthermore, studies in americium-contaminated rats
demonstrated that C2E5 administered orally enhanced 241Am
decorporation (17,50).
CONCLUSIONS
The penta-ethyl ester of DTPA (C2E5) was incorporated
into a nonaqueous gel comprised of ethyl cellulose and
Miglyol 840 using the solvent evaporation method, and was
characterized by thermal and rheological analysis and in vitro
release. A superior pharmacokinetic profile of C2E5 metab-
olites, including DTPA, was achieved when C2E5 was
administered as a nonaqueous gel as opposed to a neat oil,
perhaps as a result of permeation enhancement by Miglyol
840 and ethanol. These findings demonstrate that transdermal
delivery of a chelator prodrug is a viable approach for
delivering DTPA and other chelating agents to the circulation
as a potential treatment of transuranic radionuclide contam-
ination and provide additional understanding of the proper-
ties of nonaqueous gel formulations as well as their utility in
applications requiring transdermal and topical delivery of
moisture-sensitive drugs.
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